Pediatrix Medical Group, Inc. financials

MD CIK 0000893949

Source: EDGAR filings · Built 2026-06-02T03:31:53Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
EBITDA 230.64M -36.49M 43.49M 208.32M 235.06M 126.57M
Working Capital 304.60M 205.50M 94.51M 1.01M 413.20M 1.11B
Net Debt 262.30M 431.25M 626.50M 704.31M 677.57M 647.18M
Operating Margin 10.91% -3.41% 0.37% 8.76% 10.62% 5.66%
Net Margin 8.64% -4.92% -3.03% 3.36% 6.85% -45.93%
Return on Equity (ROE) 19.10% -12.95% -7.11% 7.44% 14.61% -106.56%
Return on Assets (ROA) 7.36% -4.60% -2.72% 2.83% 4.81% -23.79%
Current Ratio 1.66× 1.47× 1.24× 1.00× 1.97× 3.49×
Debt-to-Equity 0.74× 0.86× 0.82× 0.80× 1.19× 2.37×
Effective Tax Rate 23.58% 2.24% -24.92% 23.11% 20.14% 234.02%
Cash Conversion Ratio 1.64× -2.09× -2.27× 2.52× 0.59× -0.26×
Accruals Ratio -0.05× -0.14× -0.09× -0.04× 0.02× -0.30×
SBC % of Revenue 0.94% 0.59% 0.62% 0.82% 0.99% 2.25%

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 11.03× 18.81× 17.78×
EV / EBITDA 8.83× 32.37× 9.30× 12.89× 21.71×
P/S 0.93× 0.56× 0.39× 0.63× 1.23× 1.21×
P/B 2.05× 1.47× 0.92× 1.38× 2.62× 2.81×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Operating Expenses 1.71B 2.08B 1.99B 1.80B 1.71B 1.64B
Operating Income (Loss) 208.81M -68.71M 7.32M 172.69M 202.92M 98.13M
Income Tax Expense (Benefit) 51.04M -2.27M 12.05M 18.81M 27.24M 16.73M
Net Income (Loss) Attributable to Parent 165.39M -99.07M -60.41M 66.33M 130.96M -796.49M
Earnings Per Share, Basic $1.97 $-1.19 $-0.73 $0.79 $1.54 $-9.55
Weighted Average Number of Shares Outstanding, Basic 84.44M 83.33M 82.20M 83.47M 84.83M 83.39M
Earnings Per Share, Diluted $1.94 $-1.19 $-0.73 $0.79 $1.53 $-9.55
Weighted Average Number of Shares Outstanding, Diluted 85.43M 83.33M 82.20M 84.12M 85.83M 83.39M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 375.24M 229.94M 73.26M 9.82M 387.39M 1.12B
Assets, Current 763.51M 639.61M 483.45M 427.99M 840.56M 1.55B
Assets 2.25B 2.15B 2.22B 2.35B 2.72B 3.35B
Long-term Debt 611.20M 622.20M 637.20M 989.70M 1.70B
Liabilities, Current 458.91M 434.11M 388.95M 426.98M 427.37M 444.33M
Liabilities 1.38B 1.39B 1.37B 1.46B 1.83B 2.60B
Stockholders' Equity Attributable to Parent 865.85M 764.94M 849.06M 891.63M 896.49M 747.49M
Common Stock, Shares, Outstanding 82.98M 85.87M 84.02M 82.95M 86.42M 85.59M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 271.09M 206.57M 137.32M 166.94M 76.74M 204.62M
Net Cash Provided by (Used in) Investing Activities -18.30M -35.41M -48.18M -56.95M -53.07M 815.51M
Payments for Repurchase of Common Stock 86.68M 1.70M 919.00K 88.51M 4.72M 8.49M
Net Cash Provided by (Used in) Financing Activities -107.49M -14.48M -25.71M -487.55M -760.12M -4.16M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (MD CIK 0000893949), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

RARE

ULTRAGENYX PHARMACEUTICAL INC.

ARTV

Artiva Biotherapeutics, Inc.

HAFC

HANMI FINANCIAL CORPORATION